Latest Breaking News On - Special protocol agreement - Page 1 : comparemela.com

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression

Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that.

United statesJonathan javittDaniel javittSource nrx pharmaceuticals incUs national institutes of healthExchange commissionTherapeutics incAmerican society of clinical psychopharmacologySpecialty pharmaceutical companyNrx pharmaceuticalsNrxp nrx pharmaceuticalsCompany special protocol agreementPrnewswire nrx pharmaceuticals incSecurities exchangeEffect sizeAmerican society

Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study - NRX Pharmaceuticals (NASDAQ:NRXP)

NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.

Nrx pharmaceuticals incSuicidal bipolarMontgomery asberg depression rating scaleColumbia suicide severity rating scaleBlack boxSpecial protocol agreementNew drug approval

NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

RADNOR - NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar.

United statesJonathan javittMatthew duffyAndrew nierenbergJeremy fefferExchange commissionLotus pharmaceuticals incTherapeutics incAlvogen incNrx pharmaceuticalsUs national institutes of healthNrx pharmaceuticals incSpecialty pharmaceutical companySecurities exchangeTreatment resistant bipolar depression studyBreakthrough therapy designation

NRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study

Biopharmaceutical company NRx Pharmaceuticals, Inc. (NRXP) announced Monday that it has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.

Alvogen incLotus pharmaceuticals incNrx pharmaceuticals incTreatment resistant bipolar depression studyLotus pharmaceuticalsBreakthrough therapy designationFast track designationBiomarker letterSpecial protocol agreementSuicidal treatment resistant bipolar

NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJonathan javittAndrew nierenbergNrx pharmaceuticalsAlvogen incNrx pharmaceuticals incNrxp nrx pharmaceuticalsLotus pharmaceuticals incTreatment resistant bipolar depression studyLotus pharmaceuticalsBreakthrough therapy designationFast track designationBiomarker letterSpecial protocol agreementSuicidal treatment resistant bipolarSevere bipolar depression